Literature DB >> 33762948

Chronic Drug-Induced Liver Injury: Updates and Future Challenges.

Qiaoling Wang1,2, Ang Huang2, Jia-Bo Wang2,3, Zhengsheng Zou1,2.   

Abstract

Chronic drug-induced liver injury (DILI), defined as DILI with persistent liver injury more than one year after the first onset by the latest European guidelines, is a notable challenge globally with big issues of defining causality and establishing effective treatment. About 20% of patients with DILI develop into chronic DILI. Chronic DILI manifests as persistent or repeated inflammatory or diminishing bile ducts, even progresses to cirrhosis and needs liver transplantation eventually. However, research on chronic DILI over the last decades is still lacking, and the incidence, phenotypes, mechanisms, risk factors, and treatment have not been fully understood. In this paper, we reviewed the definition of chronic DILI, updated clinical studies in terms of incidence, special manifestations, and promising risk factors of chronic DILI, along with the recent progress and challenges in glucocorticoid therapy.
Copyright © 2021 Wang, Huang, Wang and Zou.

Entities:  

Keywords:  chronic drug-induced liver injury; definition; glucocorticoid; incidence; manifestations

Year:  2021        PMID: 33762948      PMCID: PMC7982586          DOI: 10.3389/fphar.2021.627133

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  5 in total

Review 1.  Mouse Models of Liver Parenchyma Injuries and Regeneration.

Authors:  Yuan Du; Wencheng Zhang; Hua Qiu; Canjun Xiao; Jun Shi; Lola M Reid; Zhiying He
Journal:  Front Cell Dev Biol       Date:  2022-05-05

Review 2.  Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review.

Authors:  Mirjana Stanić Benić; Lana Nežić; Vesna Vujić-Aleksić; Liliana Mititelu-Tartau
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

3.  Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury.

Authors:  Shuang Zhao; Haoshuang Fu; Tianhui Zhou; Minghao Cai; Yan Huang; Qinyi Gan; Chenxi Zhang; Cong Qian; Jiexiao Wang; Zhenglan Zhang; Xiaolin Wang; Xiaogang Xiang; Qing Xie
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

Review 4.  In Vitro Models for Studying Chronic Drug-Induced Liver Injury.

Authors:  M Teresa Donato; Gloria Gallego-Ferrer; Laia Tolosa
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

5.  Targeted Metabolomics Analysis of Bile Acids in Patients with Idiosyncratic Drug-Induced Liver Injury.

Authors:  Zhongyang Xie; Lingjian Zhang; Ermei Chen; Juan Lu; Lanlan Xiao; Qiuhong Liu; Danhua Zhu; Fen Zhang; Xiaowei Xu; Lanjuan Li
Journal:  Metabolites       Date:  2021-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.